LIGAND PHARMA

BE:LGDN Germany Other
Market Cap
$1.65 Million
€1.60 Million EUR
Market Cap Rank
#34780 Global
#4037 in Germany
Share Price
€164.00
Change (1 day)
-0.61%
52-Week Range
€85.50 - €181.00
All Time High
€235.16
About

LIGAND PHARMA operates in Diversified Metals & Mining.

LIGAND PHARMA (LGDN) - Total Liabilities

Latest total liabilities as of September 2024: €113.69 Million EUR

Based on the latest financial reports, LIGAND PHARMA (LGDN) has total liabilities worth €113.69 Million EUR as of September 2024.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

LIGAND PHARMA - Total Liabilities Trend (2016–2023)

This chart illustrates how LIGAND PHARMA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

LIGAND PHARMA Competitors by Total Liabilities

The table below lists competitors of LIGAND PHARMA ranked by their total liabilities.

Company Country Total Liabilities
Malu Paper Mills Limited
NSE:MALUPAPER
India ₹1.87 Billion
NANOMETRICS INC
MU:NNM
Germany €169.84 Million
Wegmans Holdings Berhad
KLSE:0197
Malaysia RM50.61 Million
Welltower OP LLC
STU:HCW
Germany €15.85 Billion
BIOGEN IDEC
MU:IDP
Germany €11.95 Billion
Neola Medical AB
ST:NEOLA
Sweden Skr4.15 Million
Elevate Service Group Inc.
V:SERV
Canada CA$2.29 Million

Liability Composition Analysis (2016–2023)

This chart breaks down LIGAND PHARMA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 12.49 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.14 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how LIGAND PHARMA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for LIGAND PHARMA (2016–2023)

The table below shows the annual total liabilities of LIGAND PHARMA from 2016 to 2023.

Year Total Liabilities Change
2023-12-31 €86.30 Million -47.75%
2022-12-31 €165.18 Million -65.33%
2021-12-31 €476.43 Million -27.01%
2020-12-31 €652.76 Million -10.30%
2019-12-31 €727.68 Million +3.97%
2018-12-31 €699.89 Million +158.04%
2017-12-31 €271.23 Million +4.20%
2016-12-31 €260.30 Million --